John Newman, an analyst from Canaccord Genuity, maintained the Buy rating on Y-Mabs Therapeutics (YMAB – Research Report). The associated price target remains the same with $26.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
John Newman has given his Buy rating due to a combination of factors, primarily focusing on the growth potential and strategic developments of Y-Mabs Therapeutics. The company has provided a revenue guidance of $75M-$90M for Danyelza in 2025, which is seen as achievable and potentially conservative, indicating room for growth. Additionally, the anticipated positive data from the GD2-SADA radiotherapy study in the second quarter of 2025 is expected to further bolster the company’s prospects.
Furthermore, the imminent dosing of the first patient in the CD38-SADA study for non-Hodgkins lymphoma highlights the ongoing expansion and application of the SADA platform. The company’s strategic expansion of clinical sites and the potential for further development in additional cancer indications, such as lung, breast, and gastrointestinal cancers, also contribute to the positive outlook. These factors collectively support the Buy rating, with a price target of $26.
In another report released yesterday, Cantor Fitzgerald also maintained a Buy rating on the stock with a $19.00 price target.